Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APBSCT) for cutaneous CD30-negative large T cell lymphoma

Bone Marrow Transplantation

Volumn 22, Issue 12, 1998, Pages 1211-1214

  Nishio, M ^a   Sawada, K ^a   Koizumi, K ^a   Tarumi, T ^a   Takano, H ^a   Endo, T ^a   Takashima, H ^a   Hashimoto, H ^a   Haseyama, Y ^a   Kobayashi, H ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Autologous peripheral blood stem cell transplantation (APBSCT); CD30 negative cutaneous large T cell lymphoma; Histological transformation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD30 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; RANIMUSTINE; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; CELL TRANSFORMATION; CONDITIONING; DERMIS; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; SKIN BIOPSY; SKIN LYMPHOMA; STAINING; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR CELL; WHOLE BODY RADIATION;

EID: 0032421333     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701508     Document Type: Article

References (24)

1. Beljaards RC, Chris JL, Meijer M et al. Primary cutaneous T cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol 1994; 172: 53-60.
2. Joly P, Charlotte F, Leibowitch M et al. Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. J Clin Oncol 1991; 11: 1994-2001.
3. Wood GS, Burke JS, Horning S et al. The immunologic and clinicopathologic heterogeneity of lymphomas other than mycosis fungoides. Blood 1983; 62: 464-472.
4. Ralfkiaer E, Saati TA, Bosq J et al. Immunocytochemical characterization of cutaneous lymphomas other than mycosis fungoides. J Clin Pathol 1986; 39: 553-563.
5. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood 1997, 90: 354-371.
6. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
7. Mckelvey EM, Gottlieb JA, Wilson HE et al. Hydroxy-daunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
8. Sawada K, Sato N, Kohno M et al. Efficacy of delayed granulocyte colony-stimulating factor after full-dose CHOP therapy in non-Hodgkin's lymphomas: a pilot study for leukocyte count oriented regimen. Leuk Lymphoma 1995; 20: 103-109.
9. Brugger W, Frisch J, Schulz G et al. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide and cisplatin. J Clin Oncol 1992; 9: 1452-1459.
10. Koizumi K, Sawada K, Nishio M et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant 1997; 20: 171-173.
11. +) anaplastic large cell lymphomas. Am J Pathol 1989; 135: 359-367.
12. Banerjee SS, Heald J, Harris M. Twelve cases of Ki-1-positive anaplastic large cell lymphoma of skin. J Clin Pathol 1991; 44: 119-125.
13. Rijlaarsdam JU, Huijgens PC, Beljaards RC et al. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 1992; 127: 524-528.
14. Esche BA, Fitzpatrick PJ. Cutaneous malignant lymphoma. Int J Radiat Oncol Biol Phys 1986; 12: 2111-2115.
15. Rudders RA, Rose ME, Delellis RA. Primary extranodal lymphoma. Response to treatment and factors influencing prognosis. Cancer 1978; 42: 406-411.
16. Paryani S, Hopper RT, Burke JS et al. Extralymphatic involvement in diffuse non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 682-691.
17. Nademanee A, Schmidt GM, O'Donnell MR et al. High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992; 80: 1130-1134.
18. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
19. Rossetti F, Deeg HJ, Hackman RC. Early pulmonary recurrence of non-Hodgkin's lymphoma after autologous marrow transplantation: evidence for reinfusion of lymphoma cells? Bone Marrow Transplant 1995; 15: 429-432.
20. Moreau P, LeTortorec S, Mahé MA et al. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotoropic non-Hodgkin's lymphoma. Bone Marrow Transplant 1994; 14: 775-778.
21. Zeitoun C, Baccard M, Marolleau JP et al. Autogreffe de moelle osseuse dans le traitement des lymphomes cutanés. Ann Derm Venereolog 1996; 123: 79-84.
22. Muche JM, Lukowsky A, Asadullah K et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T cell lymphoma. Blood 1997; 90: 1636-1642.
23. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
24. +-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-center experience. Bone Marrow Transplant 1997; 20: 927-934.